At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ASBP Aspire Biopharma Holdings Inc.
Market Closed 02-06 16:00:00 EST
1.46
+0.14
+10.61%
盘后1.39
-0.07-4.68%
19:52 EST
High1.49Low1.26Vol206.93K
Open1.35D1 Closing1.32Amplitude17.42%
Mkt Cap5.05MTradable Cap4.49MTotal Shares3.46M
T/O279.81KT/O Rate6.73%Tradable Shares3.08M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aspire Biopharma Amends Bylaws to Designate Series A Preferred Stock
Reuters  ·  06:26
Aspire Biopharma Amends Bylaws to Designate Series A Preferred Stock
Buzz Bomb Caffeine Company Showcases Sublingual Supplement at Sports Nutrition Summit
Reuters  ·  02-05 21:00
Buzz Bomb Caffeine Company Showcases Sublingual Supplement at Sports Nutrition Summit
Aspire Biopharma Subsidiary Buzz Bomb Signs Distribution Agreement with Blue Shark Beverages
Reuters  ·  02-03
Aspire Biopharma Subsidiary Buzz Bomb Signs Distribution Agreement with Blue Shark Beverages
Aspire Biopharma Holdings Announces Private Placement of Shares
Reuters  ·  01-31
Aspire Biopharma Holdings Announces Private Placement of Shares
Aspire Biopharma Signs Development Agreement with Microsize for Sublingual Aspirin
Reuters  ·  01-29
Aspire Biopharma Signs Development Agreement with Microsize for Sublingual Aspirin
Aspire Biopharma files patent application for sublingual alprazolam formulation
TIPRANKS  ·  01-20
Aspire Biopharma files patent application for sublingual alprazolam formulation
Aspire Biopharma Holdings Inc trading halted, news pending
TIPRANKS  ·  01-16
Aspire Biopharma Holdings Inc trading halted, news pending
Aspire Biopharma Announces 1-for-40 Reverse Stock Split
Reuters  ·  01-14
Aspire Biopharma Announces 1-for-40 Reverse Stock Split
Aspire Biopharma Director Surendra Ajjarapu Resigns
Reuters  ·  01-14
Aspire Biopharma Director Surendra Ajjarapu Resigns
Aspire Biopharma Advances High-Dose Sublingual Aspirin to FDA-Supported Clinical Trial
Reuters  ·  01-07
Aspire Biopharma Advances High-Dose Sublingual Aspirin to FDA-Supported Clinical Trial
Aspire Biopharma Swaps $1.75 Million Debt for Common Stock
Reuters  ·  01-06
Aspire Biopharma Swaps $1.75 Million Debt for Common Stock
Aspire Biopharma Transfers Listing to Nasdaq Capital Market After Extension Granted
Reuters  ·  2025-12-13
Aspire Biopharma Transfers Listing to Nasdaq Capital Market After Extension Granted
Aspire Biopharma Reports Q3 2025 Update and Advances Sublingual Drug Delivery Programs
Reuters  ·  2025-12-04
Aspire Biopharma Reports Q3 2025 Update and Advances Sublingual Drug Delivery Programs
BRIEF-Aspire Biopharma Holdings Files For Offering Of Up To 41.5 Million Shares By Selling Shareholder - SEC Filing
Reuters  ·  2025-12-03
BRIEF-Aspire Biopharma Holdings Files For Offering Of Up To 41.5 Million Shares By Selling Shareholder - SEC Filing
Aspire Biopharma Holdings Inc Files for Offering of up to 41.5 Mln Shares by Selling Shareholder - SEC Filing
THOMSON REUTERS  ·  2025-12-03
Aspire Biopharma Holdings Inc Files for Offering of up to 41.5 Mln Shares by Selling Shareholder - SEC Filing
Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin Product
Reuters  ·  2025-12-02
Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin Product
Aspire Biopharma Holdings Adds Dr. Mark J. Jaroszeski to Scientific Team
Reuters  ·  2025-11-26
Aspire Biopharma Holdings Adds Dr. Mark J. Jaroszeski to Scientific Team
Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Quarterly Report
Reuters  ·  2025-11-15
Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Quarterly Report
Aspire Biopharma Hldgs Q3 EPS $(0.04) Down From $(0.01) YoY, Sales $1.941K
Benzinga  ·  2025-11-14
Aspire Biopharma Hldgs Q3 EPS $(0.04) Down From $(0.01) YoY, Sales $1.941K
Aspire Biopharma Holdings Inc - on Nov 11, Entered Eloc Agreement With Arena Business Solutions - SEC Filing
THOMSON REUTERS  ·  2025-11-14
Aspire Biopharma Holdings Inc - on Nov 11, Entered Eloc Agreement With Arena Business Solutions - SEC Filing

Introduction

Company Name.
Aspire Biopharma Holdings Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York.
Issue price:
--